Latest filing published 20 Aug 2026 for Acrivon Therapeutics, Inc., €1,048. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Eric Devroe is a declared insider of Acrivon Therapeutics, Inc., with filings sourced from SEC (Form 4). We count 15 filings; the first trade dates from 14 November 2022 and the latest from 18 August 2026.
The open-market side counts 1 purchase for €15k alongside 1 sale for €1,048. On balance, insiders were net buyers of €14k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 11 share grants and 2 option exercises. 2026 to date brings 1 purchase and 1 sale.
The record was last updated on 20 August 2026 with an open-market sale (€1,048) in Acrivon Therapeutics, Inc. The clock since the last published purchase (15 January 2026) now reads 276 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations